MedDerm Associates | San Diego, CA

Research site

(Unclaimed)

Location

3965 5th Avenue, Suite 200, San Diego, California, United States of America

Site insights

Top conditions

Top treatments

Secukinumab

Risankizumab

Upadacitinib

Guselkumab

Dupilumab

PF-04965842

CP-690,550

Ustekinumab

ABBV-157

Ruxolitinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 27 total trials

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE-2)

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in pa...

Enrolling

Hidradenitis Suppurativa

Drug: Placebo 2

Drug: Placebo 1

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 1...

Active, not recruiting

Plaque Psoriasis

Drug: Apremilast

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS)

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling

Hidradenitis Suppurativa

Drug: Upadacitinib

Drug: Placebo

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Active, not recruiting

Hidradenitis Suppurativa

Drug: Placebo

Biological: Lutikizumab

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ASCEND)

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to sev...

Active, not recruiting

Plaque Psoriasis

Drug: Ustekinumab

Drug: Matching Placebo to Ustekinumab

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or...

Active, not recruiting

Hidradenitis Suppurativa

Drug: secukinumab